Imaging Assessments and Clinical Significance of Brain Frailty in Moyamoya Disease

References

1. 1.↵
   1. Kuroda S,
   2. Houkin K

   . Moyamoya disease: current concepts and future perspectives. Lancet Neurol 2008;7:1056–66 doi:10.1016/S1474-4422(08)70240-0 pmid:18940695

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Wardlaw JM,
   2. Smith C,
   3. Dichgans M

   . Small vessel disease: mechanisms and clinical implications. Lancet Neurol 2019;18:684–96 doi:10.1016/S1474-4422(19)30079-1 pmid:31097385

   CrossRefPubMed
3. 3.↵
   1. Shi Y,
   2. Thrippleton MJ,
   3. Makin SD, et al

   . Cerebral blood flow in small vessel disease: a systematic review and meta-analysis. J Cereb Blood Flow Metab 2016;36:1653–67 doi:10.1177/0271678X16662891 pmid:27496552

   CrossRefPubMed
4. 4.↵
   1. Evans NR,
   2. Todd OM,
   3. Minhas JS, et al

   . Frailty and cerebrovascular disease: concepts and clinical implications for stroke medicine. Int J Stroke 2022;17:251–59 doi:10.1177/17474930211034331 pmid:34282986

   CrossRefPubMed
5. 5.↵
   1. Barnett K,
   2. Mercer SW,
   3. Norbury M, et al

   . Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012;380:37–43 doi:10.1016/S0140-6736(12)60240-2 pmid:22579043

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Appleton JP,
   2. Woodhouse LJ,
   3. Adami A, et al

   ; ENOS Investigators. Imaging markers of small vessel disease and brain frailty, and outcomes in acute stroke. Neurology 2020;94:e439–52 doi:10.1212/WNL.0000000000008881 pmid:31882527

   CrossRefPubMed
7. 7.↵
   1. Duan Q,
   2. Lyu J,
   3. Cheng K, et al

   ; MR-STARS Investigators. MRI assessment of brain frailty and clinical outcome in patients with acute posterior perforating artery infarction. J Magn Reson Imaging 2023;59:340–49 doi:10.1002/jmri.28768 pmid:37183874

   CrossRefPubMed
8. 8.↵
   1. Bu N,
   2. Khlif MS,
   3. Lemmens R, et al

   . Imaging markers of brain frailty and outcome in patients with acute ischemic stroke. Stroke 2021;52:1004–11 doi:10.1161/STROKEAHA.120.029841 pmid:33504185

   CrossRefPubMed
9. 9.↵
   Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis et al. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo) 2012;52:245–66 doi:10.2176/nmc.52.245

   CrossRefPubMed
10. 10.↵
    1. Fazekas F,
    2. Chawluk JB,
    3. Alavi A, et al

    . MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149:351–56 doi:10.2214/ajr.149.2.351 pmid:3496763

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Potter GM,
    2. Chappell FM,
    3. Morris Z, et al

    . Cerebral perivascular spaces visible on magnetic resonance imaging: development of a qualitative rating scale and its observer reliability. Cerebrovasc Dis 2015;39:224–31 doi:10.1159/000375153 pmid:25823458

    CrossRefPubMed
12. 12.↵
    1. Wardlaw JM,
    2. Smith EE,
    3. Biessels GJ, et al

    ; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822–38 doi:10.1016/S1474-4422(13)70124-8 pmid:23867200

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Staals J,
    2. Makin SD,
    3. Doubal FN, et al

    . Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. Neurology 2014;83:1228–34 doi:10.1212/WNL.0000000000000837 pmid:25165388

    Abstract/FREE Full Text
14. 14.↵
    1. Lyu J,
    2. Ma N,
    3. Liebeskind DS, et al

    . Arterial spin-labeling magnetic resonance imaging estimation of antegrade and collateral flow in unilateral middle cerebral artery stenosis. Stroke 2016;47:428–33 doi:10.1161/STROKEAHA.115.011057 pmid:26732570

    Abstract/FREE Full Text
15. 15.↵
    1. Calviere L,
    2. Catalaa I,
    3. Marlats F, et al

    . Correlation between cognitive impairment and cerebral hemodynamic disturbances on perfusion magnetic resonance imaging in European adults with moyamoya disease: clinical article. J Neurosurg 2010;113:753–59 doi:10.3171/2010.4.JNS091808 pmid:20469988

    CrossRefPubMed
16. 16.↵
    1. Matsushima Y,
    2. Inaba Y

    . The specificity of the collaterals to the brain through the study and surgical treatment of moyamoya disease. Stroke 1986;17:117–22 doi:10.1161/01.str.17.1.117 pmid:3945975

    Abstract/FREE Full Text
17. 17.↵
    1. Wang LX,
    2. Wang H,
    3. Hao FB, et al

    . Ivy sign in Moyamoya disease: a comparative study of the FLAIR vascular hyperintensity sign against contrast-enhanced MRI. AJNR Am J Neuroradiol 2021;42:694–700 doi:10.3174/ajnr.A7010 pmid:33664105

    Abstract/FREE Full Text
18. 18.↵
    1. Sun H,
    2. Li W,
    3. Xia C, et al

    . Magnetic resonance imaging markers of cerebral small vessel disease in adults with Moyamoya disease. Transl Stroke Res 2021;13:533–42 doi:10.1007/s12975-021-00973-7 pmid:34839443

    CrossRefPubMed
19. 19.↵
    1. Komatsu K,
    2. Mikami T,
    3. Noshiro S, et al

    . Reversibility of white matter hyperintensity by revascularization surgery in Moyamoya disease. J Stroke Cerebrovasc Dis 2016;25:1495–502 doi:10.1016/j.jstrokecerebrovasdis.2016.02.035 pmid:27038979

    CrossRefPubMed
20. 20.↵
    1. Shi Y,
    2. Thrippleton MJ,
    3. Blair GW, et al

    . Small vessel disease is associated with altered cerebrovascular pulsatility but not resting cerebral blood flow. J Cereb Blood Flow Metab 2020;40:85–99 doi:10.1177/0271678X18803956 pmid:30295558

    CrossRefPubMed
21. 21.↵
    1. Crane DE,
    2. Black SE,
    3. Ganda A, et al

    . Gray matter blood flow and volume are reduced in association with white matter hyperintensity lesion burden: a cross-sectional MRI study. Front Aging Neurosci 2015;7:131 doi:10.3389/fnagi.2015.00131 pmid:26217223

    CrossRefPubMed
22. 22.↵
    1. Gouw AA,
    2. Seewann A,
    3. van der Flier WM, et al

    . Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 2011;82:126–35 doi:10.1136/jnnp.2009.204685 pmid:20935330

    Abstract/FREE Full Text
23. 23.↵
    1. Promjunyakul NO,
    2. Dodge HH,
    3. Lahna D, et al

    . Baseline NAWM structural integrity and CBF predict periventricular WMH expansion over time. Neurology 2018;90:e2119–26 doi:10.1212/WNL.0000000000005684 pmid:29769375

    Abstract/FREE Full Text
24. 24.↵
    1. Thomas AJ,
    2. O’Brien JT,
    3. Barber R, et al

    . A neuropathological study of periventricular white matter hyperintensities in major depression. J Affect Disord 2003;76:49–54 doi:10.1016/s0165-0327(02)00064-2 pmid:12943933

    CrossRefPubMed
25. 25.↵
    1. Moody DM,
    2. Brown WR,
    3. Challa VR, et al

    . Cerebral microvascular alterations in aging, leukoaraiosis, and Alzheimer’s disease. Ann N Y Acad Sci 1997;826:103–16 doi:10.1111/j.1749-6632.1997.tb48464.x pmid:9329684

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Zhu B,
    2. He L

    . Transient ischemic attack after indirect revascularization surgery for pediatric patients with moyamoya disease: a retrospective study of intraoperative blood pressure. Anaesth Crit Care Pain Med 2023;42:101168 doi:10.1016/j.accpm.2022.101168 pmid:36309164

    CrossRefPubMed
27. 27.↵
    1. Wityk RJ,
    2. Hillis A,
    3. Beauchamp N, et al

    . Perfusion-weighted magnetic resonance imaging in adult moyamoya syndrome: characteristic patterns and change after surgical intervention: case report. Neurosurgery 2002;51:1499–505; discussion 1506 doi:10.1097/00006123-200212000-00023 pmid:12445358

    CrossRefPubMed
28. 28.↵
    1. Pu Y,
    2. Liu X,
    3. Wang Y, et al

    ; CHANCE Investigators. Higher early recurrence risk and potential benefit of dual antiplatelet therapy for minor stroke with watershed infarction: subgroup analysis of CHANCE. Eur J Neurol 2020;27:800–08 doi:10.1111/ene.14156 pmid:31997490

    CrossRefPubMed
29. 29.↵
    1. Cho HJ,
    2. Jung YH,
    3. Kim YD, et al

    . The different infarct patterns between adulthood-onset and childhood-onset moyamoya disease. J Neurol Neurosurg Psychiatry 2011;82:38–40 doi:10.1136/jnnp.2009.181487 pmid:20587492

    Abstract/FREE Full Text
30. 30.↵
    1. Brown R,
    2. Benveniste H,
    3. Black SE, et al

    . Understanding the role of the perivascular space in cerebral small vessel disease. Cardiovasc Res 2018;114:1462–73 doi:10.1093/cvr/cvy113 pmid:29726891

    CrossRefPubMed
31. 31.↵
    1. Liu ZW,
    2. Han C,
    3. Wang H, et al

    . Clinical characteristics and leptomeningeal collateral status in pediatric and adult patients with ischemic Moyamoya disease. CNS Neurosci Ther 2020;26:14–20 doi:10.1111/cns.13130 pmid:31875482

    CrossRefPubMed
32. 32.↵
    1. Yamada I,
    2. Murata Y,
    3. Umehara I, et al

    . SPECT and MRI evaluations of the posterior circulation in Moyamoya disease. J Nucl Med 1996;37:1613–17 pmid:8862293

    Abstract/FREE Full Text
33. 33.↵
    1. Rocha M,
    2. Jovin TG

    . Fast versus slow progressors of infarct growth in large vessel occlusion stroke: clinical and research implications. Stroke 2017;48:2621–27 doi:10.1161/STROKEAHA.117.017673 pmid:28794271

    FREE Full Text